Ageless Biotech Inc, Sheridan, WY, a biotech company created to bring stem cell-based therapeutics to market, has acquired a US Food and Drug Administration (FDA) Investigational New Drug Application (IND) for the treatment of osteoarthritis of the knee.

“The acquisition of a Stage II OA of the Knee Clinical Trial allows us to start trials more rapidly with plans to start by the end of March 2022. This FDA Accepted IND allows Ageless Biotech to bring an Osteoarthritis Stem Cell product to both Physicians and Patients rapidly,” Vince Liguori, the president of Ageless Biotech Inc, points out.

The IND utilizes minimally manipulated Adipose Derived Stem Cells without enzymes or other chemicals through a proprietary process of a well-known method referred to as Stromal Vascular Fraction (SVF) which creates a matrix of live human cells. Ageless Biotech plans to prove the regenerative properties of the Ageless Biotech SVF Product before the end of this FDA Accepted Clinical Study while at the same time demonstrating the safety and minimal downtime for a patient.

The company believes that millions of annual knee surgeries will be replaced with one simple knee injection. While the company believes this technology will eventually be licensed to physicians for mass distribution, they are exploring “off the shelf” HLA Type Compliant options to complement such therapies in the “not so distant” future.

“We at BioXstem are so excited to be an active Ageless Biotech investor in that now we are not just talking about it. We can actually say that we are actively taking part in an FDA IND and part of the leadership advancing medicine,” BioXstem National Sales Director, and Ageless Biotech Board Member Jon Youngs says.

[Source(s): Ageless Biotech Inc, PR Newswire]